Fat loss

22 April 2021

Views: 322

Appetite
Drugs, Compounds, Supplements [1] Alpha-3 beta-4 nicotinic receptor (α3β4 nAChR) agonists
Drugs, Compounds, Supplements [2] beta-2 nicotinic receptor (α4β2 nAChR) agonists
Drugs, Compounds, Supplements [3] Alpha-7 nicotinic acetylcholine receptor (α7 nAChR) agonists
Drug [4], compounds [5], 2,4-diarylaminopyrimidine [6] Anaplastic Lymphoma Kinase (ALK) antagonists
Imipramine [7], LSD [8], 7,8-DHF [9] Brain Derived Neurotrophic Factor (BDNF) agonists
Sincalide [10], NN9056 [11], Lithium [12] Cholecystokinin (CCK) agonists
Cerebrolysin [13], P21 [14], Dendrobium [15] Ciliary Neurotrophic Factor (CNTF AKA GP130R) agonists
Amphetamine, Fragment peptides [16], Icariin [17] Cocaine- and amphetamine-regulated transcript (CART) agonist
Antalarmin [18], Verucerfont [19], Pregnenolone [20] Corticotropin-releasing factor (CRF) antagonists
Calcitonin [21], AM833 [22], Salmon calcitonin [23] receptor (CTR) agonists
Orlistat (THL) [24], O‐7460 [25], Cannabis extracts [26] Diacylglycerol lipase (DAGL) inhibition
Cannabidiol [27], [28], Maccamides [29] Fatty Acid Amide Hydrolase (FAAH) antagonists
Progesterone [30], TUG-891 [31], Grifolic acid [32] Free Fatty Acid Receptor 4 (FFAR4/GPR120) agonists
Fasiglifam [33], AM-1638 [34], Vincamine [35] Free fatty acid receptor 1 (FFAR1 aka GPR40) agonists
Cangrelor [36], 3-nitrophenyl 4-(4-chlorobenzamido)benzenesulfonate [37], Rapamycin [38] G Protein-Coupled Receptor 17 (GPR17) antagonists
Rimonabant [39], Compounds, Supplements [40] G Protein-Coupled Receptor 55 (GPR55) agonists
GW9508 [41], MEDICA16 [42] The combined activation of both receptors (GPR120 and GPR40) in the hypothalamus results in better metabolic outcomes than the isolated activation of either receptor alone.
Fluoxetine [43], NSI-189 [44], Royal Jelly [45] Glial cell line-derived neurotrophic factor (GDNF) agonists
Drugs [46], taspoglutide [47], resistant starch [48] Glucagon-like peptide-1 (GLP-1) agonists
Cisplatin [49], GDF15 [50], BSE [51] GDF15) GDNF family receptor alpha like (GFRAL) agonists
PYY [52], PF-5190457 [53], L-Cysteine [54] Ghrelin antagonists
Drugs [55], Plecanatide/Dolcanatide [56], TUDCA [57] Guanylyl cyclase C (GUCY2C) agonists
Psoralenoside [58], Azelastine [59], Bergapten [60] Histamine 1 (H1) receptor antagonists
Drugs [61], Lafutidine [62], This [63] Histamine 2 (H2) receptor antagonists
Pitolisant [64], Ciproxifan [65], Verongamine [66] Histamine (H3) antagonists
(Go to the GLP-1 [67] section), C75 [68], ALA [69] Hypothalamic Adenosine 5′ monophosphate-activated protein kinase (AMPK) antagonists
Moxonidine [70], LNP509 [71], Allantoin [72] Imidazoline I1-receptor (I1R) agonists
Rimonabant [73], Ginsenoside Rb1 [74], Foods [75] Leptin sensitivity
Lidocaine [76], BemPPOX [77], Pectin [78] Lingual lipase antagonists
Revefenacin [79], 4-DAMP [80], Hyoscyamine Muscarinic acetylcholine receptor M3 (M3 mAChR) antagonists?
Histamine base [81], GW803430 [82], Compound 7c [83] Melanin concentrating hormone (MCH1R) antagonists
Drugs [84], PL-8905 [85], agonists [86] Melanocortin 4 receptor (MC4R) agonists
Piperazine [87], SA57 [88], Euphol [89] Monoacylglycerol lipase (MGL) antagonists
Drugs, Compounds, Supplements [90] N-methyl-D-aspartate receptor (NMDAR) antagonists
Selegiline [91], 2-DG [92], Anthocyanins [93] Nerve growth factor (NGF) agonists
Atosiban [94], Compounds [95], EPA [96] Nesfatin-1 agonists
Compounds [97]!, Kuwanon H [98] Neuromedin B (NMB) antagonists
Cocaine [99], CPN-116 [100], p-Synephrine [101] Neuromedin-U receptor 2 (NMUR2) agonists
Vagus Nerve Stimulation [102], Orexin A (peptide), omega-3 [103] Orexin A agonists
Drugs, Compounds, Supplements [104] Trace amine-associated receptor 1 (TAAR1) agonists
Octreotide [105], SRA880 [106], Huperzine A [107] Somatostatin (SST) antagonists
Rapastinel (GLYX-13) [108], PF-4778574 [109], Crocin [110] VGF nerve growth factor inducible (VGF)

Behavioral consumption
Lorcaserin [111], Compounds [112], Oleamide [113] 5-HT receptor 2C (5-HT2C) agonists: aggravation-induced anxiety, depression, and hunger for carbs and tryptophan-heavy foods.
Acomplia [114], AM 6527 [115], Voacamine [116] Cannabinoid receptor 1 (CB1) antagonists: anorexia, binge eating, stress, and satiety impairment.
Cannabinor [117], JWH-015 [118], Cannabichromene [119] Cannabinoid receptor 2 (CB2) agonists: anxiety?
Bromocryptine, Quinpirole [120], FHGE [121] Dopamine 2 receptor (D2R) agonists: anhedonia/motivational depression and addiction (if symptoms worsen, go to the GDNF section)
Sodium salicylate [122], SAFit2 [123], silymarin and silibinin [124] FK506-binding protein 5 (FKBP51) antagonists: stress & depression from pain, PTSD, and addiction.
Levorphanol [125], compounds [126], Bovine extract [127] G Protein-Coupled Receptor 7 (GPR7 AKA NPBW1): inflammatory pain
Fluoxetine [128], Galantide [129], Celastrol [130] Galanin antagonists: addiction, too comfortable, and depression.
Drugs, Compounds, Supplements [131] Gamma aminobutyric acid (GABA) agonists: glutamatergic-induced anxiety (excitement)
Quinine [132], 2-APB [133], Theophylline [134] Inositol 1,4,5-trisphosphate receptor 3 type 3 (IP3R3) antagonists: desire for bitter, sweet and umami foods
Drugs, Compounds, herbals [135] κ-opioid receptor (KOR) antagonists: stress & drug seeking behavior.
Nicotine [136], NPSR-107I [137], Neuropeptide S spray Neuropeptide S (NPS) agonists: fear-induced anxiety.
Metreleptin (a leptin analog) [138], JNJ-31020028 [139], Chuan Xiong extract [140] Neuropeptide Y (NPY) antagonists: drowsiness, PTSD/anxiety, depression, and craving for carbohydrates.
Drugs [141], GSK1521498 [142], Oryzatensin [143], Corynantheidine [144] μ-opioid receptor (MOR) antagonists: hedonistic-binge eating.
Drugs, Compounds, Supplements [145] mGluR5 antagonists: addiction.
Colchicine [146], BCML [147], GABA [148] The bitter taste receptor 4 (TAS2R4) antagonists: hedonic hunger and addiction.
Thienorphine [149], LY2940094 [150], Curamin [151] Nociceptin-opioid-peptide (NOP) antagonist: depression and need for reward.
Carbetocin [152], Demoxytocin [153], Oxytocin spray [154] Oxytocin receptor (OXTR) agonists: loneliness.
Aripiprazole [155], DPDPE [156], Vitamin B6 [157] Prolactin reducers: quiescence, low mood, and anxiety.
Amiloride [158], 2,4-DP [159], Gymnema sylvestre [160] Taste receptor type 2/3 (T1R2/3) antagonists: hedonistic preference for sweets.
Enterostatin [161]
Glyburide [162], CBA [163], 9-phenanthrol [164] Transient receptor potential melastatin 4 channel (TRPM4) antagonists: lusts for sweet, bitter or savory foods.
Quinidine [165], TPPO [166], Zinc [167] Transient receptor potential melastatin 5 (TRPM5) antagonists: desire for bitter, sweet and umami foods

Dietary absorption
Drugs [168], Ceftezole [169], herbals [170] α-Glucosidase (GCase) antagonists
TSH [171], Atglistatin [172], bromoenol lactone [173]? Adipose triglyceride/triacylglycerol lipase (ATGL) antagonists
Lintitript (Through CCK induction) [174], Tendamistat [175], Tiliroside [176] Amylase antagonists
Volixibat [177], IMB17-15 [178], EGCG [179] Apical sodium-bile acid transporter (ASBT, SLC10A2) antagonists
Ezetimibe [180], FM-VP4 [181], Phytosterols [182] Cholesterol/Sterol absorption inhibitors
Vildagliptin [183], 5,5,5-Trifluoro-1-(dodecyloxymethyl)-4-oxopentyl decanoate [184], Ajoene [185] Gastric lipase antagonists
Sodium valproate [186] [187], Curcumin [188] Glucose transporter 1 (GLUT1) antagonists
Atenolol [189], DEHP [190], Herbals [191] Glucose transporter 2 (GLUT2) antagonists
Cetilistat [192], GT 389-255 [193], Herbal version [194] Pancreatic lipase antagonists
Acarbose [195], ACA and ONO‐RS‐082 [196], Supplements [197] Pancreatic amylase antagonists
TRH [198], GalG2CNP [199], Black tea [200] Salivary amylase antagonists
Haloperidol [201], Valiolamine [202], L-Arabinose [203] Sucrase antagonists

Insulin resistance
Drugs, experimental chemicals, and herbals [204] 5-lipoxygenase (5-LO) antagonists
Drugs, experimental chemicals, and herbals [205] (12-LO) antagonists
Sildenafil [206], LY2886721 [207], Aloeresin D [208] β-site APP cleaving enzyme 1 (BACE1) antagonists
Desipramine [209], GW4869 [210], Chamiloflan [211] Acid sphingomyelinase (ASM) antagonists
Tonapofylline [212], BW-1433 [213], Swertisin [214] Adenosine A1 receptor antagonists
Tecadenoson [215], RPR749 [216], Valerian Root [217] Selective A1AR agonists
Pemafibrate [218], CP775146 [219], Tomatidine [220] Adipose triglyceride lipase (ATGL) agonists
Triiodothyronine (T3) [221], LY570977 L-lysine [222], linoleic acid [223] Apolipoprotein A5 (APOA5) agonists
Ziritaxestat [224], PAT-505 [225], calmidazolium and vinpocetine [226] Autotaxin antagonists
Verapamil [227]?, BTT-3 [228]?, V. jatamansi rhizomes [229] β3 subunit of Cav (Cavβ3) antagonists
Atorvastatin [230], Bilirubin [231], Insulin [232] Biliverdin Reductase-a (BVR-A) agonists
Simvastatin [233], Fasitibant [234], Wortmannin [235] Bradykinin B2 receptor (B2R) antagonists
Clofibrate acid [236], BT2 [237], Probiotic yogurts [238] Branched chain ketoacid dehydrogenase kinase (BCKDK) antagonists
Fingolimod [239], JD5037 [240], Celastrol [241] Ceramide synthase 6 (CerS6) antagonists
RGZ [242], CCX832 [243], EPA [244] Chemokine like receptor 1 (ChemR23) antagonists
Cilostazol [245], Cenicriviroc [246], α-Mangostin [247] Chemokine receptor-2 (CCR2) antagonists
Mifepristone [248], CORT125281 [249], Theophylline [250]? Corticosterone-induced hyperinsulinemia antagonists
Drugs [251], Compounds [252], palbociclib [253] Cyclin-dependent kinase 4&6 (CDK4&6) antagonists
Nimesulide [254], PTUPB [255], syringaldehyde [256] Cyclooxygenase-2 (COX-2) antagonists
Fomepizole [257], Chlormethiazole [258], Friedelin [259] Cytochrome P450 2E1 (CYP2E1) antagonists
Misoprostol [260], Sulprostone [261], Castor oil [262] EP3R agonists
Erythropoietin [263], CNTO 530 [264], SPN [265] Erythropoietin receptor (EPOR) agonists
Sulfisoxazole [266], Compounds [267], Sclerotiorin [268] Endothelin type A receptor (ETA R) antagonists
Fulvestrant [269], Triclocarban [270], I3C [271] Estrogen receptor 1 (ESR1) antagonists
Pioglitazone [272], Lipofermata [273], arylpiperazine derivatives [274] Fatty acid transport proteins (FATP1) antagonists
Deoxycholic acid [275], butylidenephthalide [276], ursodeoxycholic acid [277] Fatty acid transport protein 5 (FATP5) antagonists
Propranolol [278], FGL [279], GABA [280] Fibroblast growth factor 1 (FGF1/FGFR1) agonists
Testosterone [281], Rolipram [282], Forskolin [283] Forkhead box C2 protein (FOXC2) agonists
Calcitriol [284]?, U73122 [285], Forskolin [286]? G protein-coupled receptor 21 (GPR21) antagonists
Prednisolone [287], NS-3-008 hcl, Fasting [288] G0/G1 switch gene 2 (G0S2) antagonists
Acipimox [289], PX-478 [290], 4-O-demethylmanassantin B [291] selective Hypoxia-inducible factor 1α (HIF1α) antagonists
α Ceftriaxone [292], β aspirin [293] & other salicylates [294] ε Amlexanox [295] α,β, and ε Compounds [296], α Apigenin [297], β ellipticine [298], ε Malachite green [299] oxalate [300] IKKα-IKKε antagonists
Suramin [301], TNP [302], Flavonoids [303] Inositol hexaphosphate kinase 1 (IP6K1) antagonists
Anakinra [304], c(MyD 4-4) [305], Nigellidine [306] Interleukin-1 receptor (IL-1R) antagonists
Estradiol [307], Tankyrase [308], Licarin B [309] IRS-1 agonists
Enasidenib [310], AGI-6780 [311], Curcumol [312] Isocitrate dehydrogenase 2 (IDH2) antagonists
Zileuton [313], Etalocib [314], Chrysin [315] Leukotriene BLT1 antagonists
Amelubant [316], Compounds [317], γ-Linolenic Acid [318] Leukotriene B4 (LTB4) antagonists
Canrenoate [319], CDC [320], Vitamin D [321] Lipocalin-2 (LCN2) antagonists
Isoniazid [322], Compound 7f [323], Avocado Seed oil [324] Lysyl oxidase (Lox) antagonists
Spironolactone [325], Apararenone [326], Sojagol [327] Mineralocorticoid receptor (MR) antagonist
Losartan [328], SBI-797812 [329], BMSO [330] Nicotinamide Phosphoribosyltransferase (NAMPT) agonists?
Bazedoxifene [331]?, DDA [332], Monascin [333] Neuron-derived orphan receptor 1 (NOR1) agonists
Telmisartan [334], Halofenate [335], Indomethacin [336] Partial peroxisome proliferator-activated receptor gamma (PPARγ) agonists
Betamethasone [337], compounds [338], 2 rosemary extracts [339] Phosphoenolpyrovate carboxykinase (PEPCK) antagonists
Pimecrolimus [340], SPA70 [341], Sesamin [342] Pregnane X receptor (PXR) antagonists?
Ramipril [343], Azeliragon [344], Pinocembrin [345] Receptor for advanced glycation endproducts (RAGE) antagonists
Sitagliptin [346], Fenretinide [347], GMF&BRE [348] Retinol binding protein 4 (RBP4) antagonists
Drugs [349], R508 [350], 2HF [351] RLIP76 antagonists
Digoxin [352], T0901317 [353] /SR3335 [354] /S18-000003 [355], betulinaldehyde [356] Retinoic Acid-related Orphan Receptor (ROR) α/γ
Pentostam [357], TPI-1 [358], Ginkgolic acid [359] Src homology 2 domain-containing protein tyrosine phosphatase 1 (SHP-1) antagonists
Bexarotene [360], UBCS039 [361], Myristic acid [362] Sirtuin 6 (SIRT6) agonists
Infliximab [363], Benpyrine [364], Fisetin [365] TNF receptor-1 (TNFR1) antagonists
Rosuvastatin [366], Vaspin (63-104)?, Fasting [367] Vaspin agonists
CA 074, MP-CB-2 Selective Cathepsin B agonists

Lipid mobilization
Torcetrapib [368], ATR-101 [369], alpha-Tocopherol [370] ATP-binding cassette sub-family G member 1 (ABCG1) antagonists
hCG [371], SP600125 [372], Magnolol [373] Adipose differentiation-related protein (ADRP) antagonists
Valproic Acid [374], P23 [375], NDGA [376] Acyl-CoA thioesterases 2 ACOT2 antagonists
Exenatide [377], Perfluorooctanoic acid [378], Extended-release niacin [379] Apolipoprotein B-48 (ApoB48) reducers
Empagliflozin [380], Salvianolic acid b (SAB) [381], Sulfosuccinimidyl oleate [382] Platelet glycoprotein 4 (AKA CD36) antagonists
Isoproterenol [383], EPA-PL [384], Cordycepin [385] Fat‐specific protein 27 (FSP27) antagonists
Pioglitazone [386], 5k [387], ReishiMax [388] Fatty acid transport protein 1 (FATP1)
Drugs [389], CB-2 [390], L-carnitine [391] Fatty acid transport protein (FATP2) antagonists
Ezetimibe [392], Compounds [393], β-glucan [394] /Rotenone [395] Fatty acid transport protein 4 (FATP4) antagonists
Tranexamic acid [396], GW1929 [397], AELL [398] Fatty acid transport protein 6 (FATP6)
Methylxanthine drugs [399], rhLMF [400], Zinc [401] Lipid-mobilizing factor (LMF) agonists
HGH (frag 176-191 & AOD 9604) [402], Triton WR-1339 [403], seaweed extracts [404]? (adipocyte) Lipoprotein lipase (LPL) antagonists?
Drugs [405], CS-8958 [406], Herbals [407] Neuraminidase-1 (Neu1) antagonists
Prednisolone [408], Cathepsin B peptide [409], Oligonol [410] Perilipin 1 (PLIN1) antagonists
Triacsin C [411], GW9662 [412], sulforaphane [413] Perilipin 2 (PLIN2) antagonists
_____________________________________________________________________________________________________
Adipocyte browning
Testosterone [414], Efaroxan hydrochloride [415], Yohimbine HCL [416] Alpha-2 (α2) antagonists
Olanzapine [417], VK2809 [418], Dihydromyricetin [419] Autophagy-related protein 12 (ATG12) agonists
Terbutaline [420], AC261066 [421], Gramine [422] selective Beta2 (β2) agonists
Vibegron [423], CL-316,243 [424], Aegeline [425] Beta3 (β3) agonists
Flutamide [426], 4-tert-octylphenol [427], Boron [428] Bone morphogenetic protein receptor 1a (BMPR1A) agonists
Troglitazone [429], rhBMP8b, capsaicin [430] Bone morphogenetic protein 8B (BMP8B) agonists
Nicotine [431], LINC00961 [432], Linoleate [433] Cardiolipin synthase 1 (CRLS1) agonists
Dibenzazepine [434], PI-103 [435], resveratrol [436] Cell death activator (CIDEA) agonists
Cetuximab [437], Utomilumab [438], Trans-Anethole [439] Cd137 agonists
Isoproterenol [440], Cy3G [441], Theobromine [442] CITED1 agonists
Cantharidin [443], NCC-00007277 [444], Spermidine [445] CCR4-NOT transcription complex subunit 7 (CNOT7) antagonists
Ciprofibrate [446], T0901317 [447], Leoligin [448] Cholesterylester transfer protein (CETP) agonists
Cryptotanshinone [449], Palmitoyl lactic acid [450], Taurine [451] Cytochrome c oxidase polypeptide 7A1 (Cox7a1) agonists
Nicardipine [452], INT-767 [453], Obeticholic Acid [454] Farnesoid X receptor (FXR) agonists
Bevacizumab [455], 3MC [456] or SNS-032 [457]?, Ampelopsin [458]? HOXC10 antagonist
Cannabidiol [459], BAY 11-7085 [460], Genistein [461] Inhibition of differentiation 1 (Id1) antagonists
Drugs [462], DG172 [463], Baicalin [464] interferon regulatory factor 4 (IRF4) agonists
Formoterol [465], Mots-C [466], Zeaxanthin [467] Mitochondrial Biogenesis agonists
Panobinostat [468]?, 2,4-thiazolidinedione [469], DHEA [470] Nuclear respiratory factor 1 (NRF1) agonists
Azelaic acid [471] Olfactory receptor 544 (Olfr544) agonists
IMR-687, compounds [472], Paraxanthine [473] phosphodiesterase 9 (PDE9) antagonists
Drugs [474], Compounds [475], β-aminoisobutyric acid (BAIBA) [476] Peroxisome proliferator-activated receptor alpha (PPARα) agonists
Tamoxifen [477], GW6471 [478], Berberine [479] Peroxisomal Reductase Activating PPAR-gamma (PexRAP) inhibitors
Bimatoprost [480], Sulprostone [481], Tahiti lime [482] Prostaglandin E2 (PGE2) E-prostanoid receptor 3 (EP3) agonists
Simvastatin [483], Ser-102 and Ser-1003 [484], Diosgenin [485] RIP140 antagonists
Catecholamines [486] [487], Tetrandrine [488] Signal transducer and activator of transcription 3 (STAT3) agonists
Deoxycholic acid [489], INT-767 [490], Gentiopicroside [491] Takeda G-protein-coupled receptor (TGR5 AKA GPBAR1) agonists
Nobiletin [492], t10-c12 CLA [493], Xanthohumol [494] T-box transcription factor (TBX-1) agonists
Resmetirom [495], VK2809 [496], 3,5-diiodo-L-thyronine (T2) [497] Thyroid-like hormonal agonists
Drugs [498], JQ1 [499], Trichostatin A [500] Transducin-like enhancer of split 3 (TLE3) antagonists
Mirabegron [501], myostatin antagonists [502], nobiletin [503] Transmembrane protein 26 (Tmem26) agonists
Thrombin, Clemizole, Tonantzitlolone [504] Transient receptor potential 1 (TRPC1) agonists
Ligustilide [505], FLX-787 [506], (mostly) spices [507] Transient receptor potential cation channel, subfamily A, member 1 (TRPA1 AKA ANKTM1) agonists
AR-15512 [508], D-3263 [509], agonists(also Menthol) [510] Transient receptor potential cation channel subfamily M (melastatin) member 8 (TRPM8) agonists
Drugs, Compounds [511], Sparganum stoloniferum [512]? Transient receptor potential polycystin-3 (TRPP3 AKA PKD2L1) antagonists
Capsicum oleoresin [513], Qutenza [514], 8-Gingerol [515] Transient receptor potential cation channel subfamily V member 1 (TRPV1) agonists
Cyclosporine A, FK506 [516], Supplements [517] Transient receptor potential cation channel subfamily V member 2 (TRPV2) antagonists
Carbenoxolone [518], GSK205 [519], Citral [520] Transient receptor potential cation channel subfamily V member 4 (TRPV4) antagonists (might cause hypertension)
Clotrimazole [521], Scalaradial [522], Glutathione [523] receptor potential cation channel, subfamily M, member 2 (TRPM2) antagonists
Desferrioxamine [524], Epilactose [525], Fucoxanthin [526] Uncoupling protein-1 (UCP-1) agonists
Perindopril [527], Troxerutin [528], CoQ10 [529] Uncoupling protein-2 (UCP-2) agonists
Spironolactone [530], BAY-u 3405 [531], Ellagic Acid [532] ZFP423 antagonists

Adipocyte general
Clofibrate [533], 10,12-Tricosadiynoic acid [534], bilberry extract [535] Acyl-CoA oxidase (ACO) agonists
Disulfiram [536], Salinomycin [537], CM10 [538] Aldehyde dehydrogenase (ALDH1) antagonists
Eculizumab [539], NOX-D21 [540], Supplements [541] C5a antagonists (only if you're obese)
Topiramate [542], Dimethylfraxetin [543], 1,3-Dimethyluracil [544] Carbonic anhydrase (CA) antagonists
Purvalanol A [545], Butyrolactone I [546], Arecoline [547] Cyclin-dependent kinase 1 (CDK1) antagonists
Drug [548], RG-12525 [549], Bergamottin [550] Cytochrome P450 3A4 (CYP3A4) antagonists
Chiglitazar [551], Toximul [552], d-Xylose [553] Cytochrome P450, family 4, subfamily a, polypeptide 10 (Cyp4a10) agonists
Leflunomide [554], ASLAN003 [555], Orotic acid [556] Dihydroorotate dehydrogenase (DHODH) antagonists
Drugs [557], SGI-1027 [558], Genipin [559] DNA methyltransferase DNMT1 antagonists
Lubiprostone [560], CAY10580 [561], C‐8 olefinated quinoline [562] E4 agonists
Valsartan [563], C(3) [564], EGCG [565] Early growth response protein 1 (Egr1) antagonists
Diethylstilbestrol [566], GSK5182 [567], Artemisinin [568] Estrogen-related receptor γ (ERRγ) antagonists
Meclofenamic acid [569], FB23-2 [570], Rheic Acid [571] Fat mass and obesity-associated protein (FTO) antagonists
Pyrazinamide [572], Compounds, supplements [573] Fatty acid synthase (FASN) antagonists
Eltrombopag [574]?, TA-316 [575], Wogonin [576] FOG Family Member 1 (FOG1) agonists
Cromolyn [577], Zaprinast [578], Kynurenic acid [579] G protein-coupled receptor 35 (GPR35) agonists
Rosiglitazone [580], AZ1 [581], Lactate [582] G protein-coupled receptor 81 (Gpr81) agonists
Omeprazole [583], LPG1205 [584], STW5 [585] G-Protein-Coupled Receptor 84 (GPR84) antagonists
Monomethyl fumarate [586], GSK256073 [587], β-hydroxybutyrate [588] G protein-coupled receptor (GPR109A) antagonists
Fluticasone propionate + AZD8999 [589], GSK4716 [590], L‐Carnitine [591] Glucocorticoid receptor α (GRα) agonists
Maybe metformin [592], compounds [593] /iGP-1 [594], natural extracts [595] Glycerol-3-Phosphate Dehydrogenase 2 (GPDH2) antagonists
Methamphetamine [596]?, Methyl indoxam [597], Glycyrrhizin [598] Group 1B phospholipase A2 (Pla2g1b) antagonists
Clofazimine [599], Medium‐chain fatty acids [600], Sesamol [601] Hormone-sensitive Lipase (HSL) agonists
Compounds [602], 4μ8c [603], Toyocamycin [604] Inositol-Requiring Enzyme 1α/X-box binding protein 1 (IRE1α-XBP1) antagonists. XBP1s in normal circumstances induces inflammation & the genetic expression of adipocytes, however, under dietary restriction XBP1 activates sugarbabe, a Gli-like zinc-finger transcription factor, which further indirectly effects longevity. In light of this, it maybe not advised to consume these antagonists of IRE1α and/or XBP1 while fasting as they might a risk to your lifespan.
Balsalazide [605], AG-490 [606], KMU-3 [607] Signal transducer and activator of transcription 3 (STAT3) antagonists
Pravastatin [608], REN001 [609], Fats [610] Long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) agonists?
Chlorpromazine [611], Lalistat [612], Sebelipase Alfa [613] Lysosomal Acid Lipase (LAL) antagonists
Cocaine [614], UP780 [615], Soy protein [616] Malic Enzyme 1 (ME1) antagonists
Metformin [617], NPD389 [618], Embonic acid [619] Malic Enzyme 2 (ME2) antagonists.
Beloranib [620], ZGN-1061 [621], Fumagillin [622] Methionine aminopeptidase 2 (MetAP2) antagonists
Saroglitazar [623], Imeglimin [624], Isoorientin [625] Mitochondrial Bioenergetic agonists
Sorafenib [626], BAM15 [627], Emodin [628] Mitochondrial uncoupler agonists
Varespladib [629]?, 1-MNA [630], 5-amino 1mq [631] Nicotinamide N-methyltransferase (NNMT) antagonists
Calcipotriol [632], TMPA [633], Decanoic Acid [634] NUR77 antagonists
Amodiaquine [635], C-DIM12 [636], Carnosol [637] NURR1 agonists
Gefapixant [638], TNP-ATP [639], Sinomenine [640] P2X purinoceptor 3 (P2X3R) antagonists
Eplerenone [641], D-4F [642], Zinc [643] Paraoxonase 1 (PON1) agonists
Drugs and compounds [644], N-methyl-N′-nitro-N-nitrosoguanidine [645] Poly [ADP-ribose] polymerase 1 (PARP1) antagonists
Celecoxib [646], GB88 [647], NAC [648] Proteinase-activated receptor 2 (PAR2) antagonists
Calcitonin family of peptides [649], AM (22–52) [650], Intermedin [651] Receptor activity modifying proteins (RAMPs) agonists
Denosumab [652], 4-IPP [653], Rhoifolin [654] Receptor activator of nuclear factor κB ligand (RANKL) antagonists
Methotrexate [655], PF-9366 [656], Lectin [657] S-Adenosylmethionine synthetase (SAMS) antagonists
Dactinomycin [658], Idebenone [659], GSE [660] Shc antagonists
Tamoxifen [661], ZINC12421989 [662], Rapamycin [663] Sirtuin 4 (SIRT4) antagonists
Regorafenib [664], AR9281 [665] / Compounds [666], Inula helenium extracts [667] soluble Epoxide Hydrolase (sEH) antagonists
Atorvastatin [668], MK-8245 [669], Sterculic Acid [670] Stearoyl-CoA desaturase (SCD) antagonists
Metformin [671], NF-56-EJ40 [672], Glutamine [673]? Succinate Receptor 1 (SUCNR1 aka GPR91) antagonists
Paracetamol [674], GFB-8438 [675], Ginger extract [676] Transient receptor potential 5 (TRPC5) antagonists?
Rosiglitazone [677], Sodium sulfite [678], EPA [679] triglyceride hydrolase (TGH-1) agonists
Telotristat ethyl [680], Compound 23a [681], Kanna [682] Tryptophan hydroxylase (TPH1) antagonists
Rhodamine [683], [R16]‐PACAP (1–23) [684], VIP [685] Vasoactive intestinal polypeptide receptor 1 (VPAC1) agonists?
Vasomera [686], BAY 55-9837 [687], [R16]‐PACAP (1–27) [688] intestinal polypeptide receptor 2 (VPAC2) agonists?

Cardiac
Sex hormones [689], Nicotine [690], retinoic acid [691] Acylation-stimulating protein (ASP) antagonists
Colesevelam [692], Anacetrapib [693], Niacin [694] APOE*3-Leiden.CETP antagonists
Disulfiram [695], CVT-10216 [696], Taraxerone [697] Aldehyde dehydrogenase (ALDH2) antagonists
Epalrestat [698], Compuunds, Supplments [699] Aldose Reductase antagonists
Cyclosporine [700], GW4064 [701], L-citrulline [702] Cationic amino acid transporter-1 (CAT1) agonists
Plerixafor [703], 6r [704], Melatonin [705] Cathepsin S (CTSS) antagonists
Quinoxaline [706], BMS309403 [707], Urea [708] Fatty acid binding protein 4 (FABP4 aka ap2) antagonists (inhibits browning)
Sialic acid [709] Fc region of immunoglobulin gamma region receptor II-b (FcγRIIb) antagonists
Paroxetine [710], GSK180736A [711], Balanol [712] G protein-coupled receptor kinase 2 (GRK2) antagonists
Fostamatinib [713], Lanraplenib [714], Shikimic acid [715] Glycoprotein VI (GPVI) antagonists
Lomitapide [716], JTT-130 [717], Ginkgetin & Dauricine [718] Microsomal triglyceride transfer protein (MTP) antagonists
Tocilizumab [719], MCC950 [720], Hyperin [721] Nod-like receptor family pyrin domain containing 3 (NLRP3) antagonists
Ezetimibe [722], SB230580 [723], Mangiferin [724] Oxidized low-density lipoprotein (oxLDL) reducers
Drugs [725], AZD1283 [726], Sterol sulfate [727] Purinergic receptor P2Y12 antagonists
Fasudil [728], Y-27632 [729], β-Elemene [730] Rho-kinase antagonists
Topiramate [731], Peptide H11 [732], Nobiletin [733] Scavenger receptor (SR-A) antagonists
Ramatroban [734], Dazmegrel [735], Imidazole [736] Thromboxane-A synthase antagonists
Diclofenac [737], Terutroban [738], NV-52 [739] Thromboxane-Prostanoid Receptor (TP-R) antagonists
Pravastatin [740], rhRAP [741], Red yeast rice [742] Very low-density lipoprotein receptor (VLDLR) reducers

Hepatic
Drugs [743], Ebselen [744], Physcion [745] 6-Phosphogluconate Dehydrogenase (6PGD) antagonists
Indiplon [746], BJ-B11?, OLE [747] Arylacetamide deacetylase (AADAC) agonists
Chloroquine [748], nor-NOHA [749], Rhizomes [750] Arginase antagonists
Abemaciclib [751], 2,4-diaryl 7-azaindole [752], Zyflamend [753] Calcium/calmodulin-dependent protein kinase kinase 2 (CaMKK2) antagonists
Ketamine [754], ML-210 [755], Vitamin b15 [756] Glutathione peroxidase (Gpx) antagonists
Raloxifene [757], m-aminophenylboronate [758], APE [759] Hepatic triglyceride lipase (HTGL) antagonists
Drugs [760], SR12813 [761], Bergamot Flavonoids [762] HMG-CoA Reductase (HMGCR) antagonists
Treprostinil [763], MRE-269 [764], Acetylsalicylic acid [765] I prostanoid receptor (IP) agonists?
OGT [766], l-1-methyl-tryptophan [767], α-naphthoflavone [768] Indoleamine 2,3-dioxygenase 1 (IDO1) antagonists
Gemigliptin [769], Oprozomib [770]?, Concanavalin A [771] Leukocyte cell–derived chemotaxin 2 (LECT2) antagonists
Sorafenib [772], V-P complex [773], Ursolic acid [774] Liver kinase B1 (LKB1) agonists
Sitosterol [775], IMB-170 [776], Rhein [777] Liver X Receptor α (LXRα) agonists?
Sophoricoside [778], GSK2033 [779]?, Riccardin C [780] Liver X Receptor β (LXRβ) antagonists
Carvone [781] Olfactory receptor 43 (Olfr43) agonists
Dipyridamole [782], Lys-305 [783], Lycorine [784] SREBF chaperone (SCAP) antagonists
Betulin [785], β-HIVS [786], Fla-CN [787] Sterol regulatory element binding protein (SREBP-1c) antagonists
Artesunate [788], AI-1l [789], Osmotin [790] Sterol regulatory element-binding protein-2 (SREBP-2) antagonists
Valsartan [791], CH-223191 [792], Naringenin [793] Toll-like Receptor 2 (TLR2) agonists

Hyperglycemia
Lisinopril [794], Epostane [795], Glycyrrhyzic acid [796] 17-hydroxyprogesterone (17-OHP) antagonists
DALDA [797], Ceapin-A7 [798], Tunicamycin [799] Activating transcription factor 6 (ATF6) agonists
Nifedipine [800], Compounds [801], Oxymatrine [802] Adenosine A2b receptor (ADORA2B) antagonists
Telmisartan [803]?, MSG [804], Embelin [805] Adipsin agonists
Mefenamic acid [806], ASP-9521 [807], Liquiritin [808] Aldo-keto reductase family 1 member C (AKR1C) antagonists
Mosapride citrate [809], TCPOBOP [810], Galangin [811] Constitutive androstane receptor (CAR) agonists (mice CAR agonists seem to act as inverse agonists to human CARs.)
NSAIDs [812], Gly-β-MCA [813], Guggulsterone [814] glycoursodeoxycholic acid [815] Farnesoid X receptor (FXR) antagonists?
Edetic acid [816], Compounds [817] VK0612 [818], Achyrofuran [819] Fructose-1,6-bisphosphatase-1 (FBPase-1) antagonists
Adomeglivant [820], MK-0893 [821], L. coromandelica extract [822] Glucagon Receptor (GR) antagonists
Drugs [823], C113176 [824], Olea europaea extract [825]? Glucocorticoid receptor II (GRII)
Bile acids [826] (like Ursodiol [827]), Compounds [828], Chlorogenic acid [829] Glucose 6-phosphatase (G6pase) antagonists
Latanoprost [830], HX-531 [831], D'orenone [832] Retinoid X receptor (RXR) antagonists
Tazarotene [833], AC-55649 [834], Vitamin A [835] Retinoic acid receptor (RARβ) agonists
Prolactin [836], Dorzagliatin [837], Vanadium [838] Glucokinase activators
Doxorubicin [839], Aminoguanidine [840], Glycine [841] Glyoxalase 1 (Glo1) agonists
Hydralazine [842]?, FG-4497 [843], dealanylalahopcin [844] Hypoxia-inducible factor Prolyl 4-hydroxylases (HIF-P4H) antagonists
Estradiol-17β [845], Compounds [846], DMAMCL [847], fructose 1,6-bisphosphate [848] Pyruvate kinase isoenzyme M2 (PKM-2) activator
Drugs [849], Tofogliflozin [850], Trilobatin [851] Sodium/glucose cotransporter 2 (SGLT2) antagonists
(Potential) drugs [852], CTPIs & BTA [853], 2:1 Brutieridin & Melitidin flavonoids (BMF) [854] Solute Carrier family 25 member 1 (SLC25A1) antagonists
Diazoxide [855], Mitiglinide calcium [856], Hesperidin [857] Sulfonylurea receptor 1 (SUR1) antagonists
Docetaxel [858], Oxythiamine [859], Avemar [860] Transketolase (TKT) antagonists
Erlotinib [861], Azaserine [862], Kainic Acid [863] Tribbles homolog 3 (TRIB3) antagonists

Myogenetic
Levophed [864], Compounds, Supplement [865] 2-deoxyglucose transport (dGlc) agonists
Sulindac [866]?, Ciglitazone [867], β-Glycyrrhetinic acid 15-Hydroxyprostaglandin dehydrogenase (15-PGDH) antagonists
Carbenoxolone [868], CNX-010-49 [869], Emodin [870] dehydrogenase type 1 (11β-HSD1) antagonists
Bortezomib [871], LY3009120 [872], CGOSE [873] Acetyl-CoA carboxylase (ACC) antagonists
Regadenoson [874], KF21213 [875], Inosine [876] Adenosine A2a receptor (ADORA2A) agonists
Dapagliflozin [877], AdipoRon [878], curcumin [879] Adiponectin receptor (AdipoR) agonists
Dexrazoxane [880], JDP2 [881], Coffee [882] Activating transcription factor 3 (ATF3) antagonists
Febuxostat [883]? GSK621 [884], Supplements [885] Activating transcription factor 4 (ATF4) antagonists
Bimagrumab [886], CDD866 [887], Alantolactone [888] Activin type II receptor (ActRII) antagonists
Apelin peptide, CMF-019 [889], CBD [890]? Apelin agonists
Sulfonylurea [891] drugs [892], U0126 [893], Bakuchiol [894] Baf60c (also called Smarcd3) modulator
rhBMP-7 [895], LPP [896], Hwanggeumchal sorghum extract [897] Bone morphogenetic protein 7 (BMP-7) agonists
Clozapine [898], Wy14643 [899], Ursolic acid [900] Carnitine palmitoyltransferase 1 (CPT1) agonists
Viagra [901], Compounds [902], Danshen [903] Collagen receptor integrin α2β1 antagonists
Cyclosporine [904], Dehydrosinulariolide [905], Da-Bu-Yin-Wan [906] DJ-1 agonists
Drugs [907], WAY-262611 [908], Gastrodin [909] Dickkopf-1 (DKK1) reducers
Erlotinib [910], AG-1478 [911], Mevastatin [912] Epidermal growth factor receptor (EGFR) antagonists
Clomifene, β-LGND2 [913], Saikosaponin D [914] Estrogen receptor-β (Erβ AKA ESR2) agonists
Fluvastatin [915], AICAR [916], MWPS [917] Fatty acid binding protein/aspartate aminotransferase (FABPpm/AspAT) agonists
FGF21 drugs [918], YH25724 [919], Sodium Butyrate [920] Fibroblast growth factor 21 (FGF21) agonists
Entacapone [921], AS1708727 [922] , Marein [923] Forkhead box protein O1 (FOXO1) antagonists
Fenofibrate [924], KD025 [925], compound 27 [926] Glycogen synthase kinase 3 (GSK-3α) antagonists
Sodium Valproate [927], Indirubin-3ʹ-monoxime [928], Acacetin [929] Glycogen synthase kinase 3 (GSK-3β) antagonists
Trecadrine [930], BRL37344 [931], Oleanolic acid [932] Glucose transporter type 4 (GLUT4) upregulators
Doxycycline [933]?, rGDF3 [934], 5,7-dimethoxycoumarin [935] Growth differentiation factor 3 (GDF3) agonists?
Obeticholic Acid [936], GW0742 [937], Silibinin [938] Insulin induced gene-1 (Insig-1) agonists
GLP-2 analogues [939] like Teduglutide, L-783,281 [940], Protein [941] Insulin receptor tyrosine kinase (IRTK) agonists
SERMs [942], IGF-1 DES [943], whole-body vibration [944] Irisin agonists
Bromocriptine [945], Ibrolipim [946], Hawthorn [947] (muscle) Lipoprotein lipase (LPL) agonists?
Lixisenatide [948], LY379268 [949], Rutin [950] Mitochondrial transcription factor A (TFAM) agonists
Etanercept [951], PF-06260933 [952], Militarinone alkaloids [953] Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4k4) antagonists
Sorafenib [954] ?, NSC 95397 [955], Triptolide [956] Mitogen-activated protein kinase (MKP-1) antagonists
Bleomycin [957], Elamipretide [958], Xanthophylls [959] Mitochondrial-targeted catalase (MCAT) agonists
Lovastatin [960], (E)-SIS3 [961], Chebulinic acid [962] Mothers against decapentaplegic homolog 3 (SMAD3) antagonists?
Dulaglutide [963], BRL-47672 [964], Kazinol-P [965] Myoblast determination protein 1 (MyoD) agonists
Bexarotene [966], YK11 [967], HSP [968] Myogenic factor 4 (Myogenin AKA MyoG) agonists
Allopurinol [969], IMB0901 [970], PMI5011 [971] Muscle Atrophy F-box (MAFbx A.K.A. Atrogin-1) antagonists
Nesiritide [972], PL3994 [973], Leonuridine [974] Natriuretic peptide receptor-A (NPR-A) agonists
Diprivan [975], Umbelliferone [976], Dibenzoylmethane [977] (licorice phenylpropanoids in general) Nuclear factor erythroid 2 (NRF2) agonists
Pilocarpine [978], MRS2957 [979], Uridine [980] Purinergic receptor P2Y6 agonists
Indomethacin A [981], MB-3 [982], PQQ [983] Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α) agonists
Cilostazol [984], compounds [985], GE [986] Phosphodiesterase 3 (PDE3B) antagonists
Roflumilast [987], GSK256066 [988], Luteolin [989] phosphodiesterase‐4 (PDE4) antagonists
Mirabegron [990], Dialauroylphosphatidylcholine [991], Red raspberry extract [992]? Perilipin 5 (PLIN5 A.K.A OXPAT) agonists
Drugs,17, Plasma cell membrane glycoprotein 1 (PC-1 AKA ENPP1) antagonists
Olaparib [993], UPF 1069 [994], Naringin [995] Poly [ADP-ribose] polymerase 2 (PARP2) antagonists
Pitavastatin [996], VGVAPG [997], Kaempferol [998] Preadipocyte factor-1 (Pref-1 A.K.A DLK1) agonists
CZH [999], rhPRMT7, Apigenin [1000] Protein arginine methyltransferase 7 (Prmt7) agonists
Drugs [1001], SBC-115076 [1002], Pinostrobin [1003] Potent extracellular proprotein convertase subtilisin kexin type 9 (PCSK9) antagonists
Ertiprotafib [1004], KY-226 [1005], Psoralidin [1006] Protein tyrosine phosphatase 1B (PTP1B) antagonists
Dichloroacetic acid [1007], AZD7545 [1008], Sodium dichloroacetate [1009] Pyruvate dehydrogenase kinase (PDHK) antagonists
Latanoprost [1010], M77976 [1011], TSA [1012] Pyruvate dehydrogenase kinase 4 (PDK4) antagonists
Evogliptin [1013], bpV(phen) [1014], Afzelin [1015] Phosphatase and tensin homolog (PTEN) antagonists
Heme [1016], SR6452 [1017], L-Arginine [1018] Rev-erb agonists
mTORC1 antagonists [1019], GSK-25 [1020], Eudesmin [1021] S6 kinase (S6K) antagonists
Dabrafenib [1022], MRT199665 [1023], I3M [1024] Salt inducible kinase 1 (SIK1) antagonists
Drugs [1025], rhSPARC [1026], Phytoestrogens [1027] Secreted protein acidic and rich in cysteine (SPARC AKA Osteonectin) agonists?
Trichostatin A [1028], MS-275 w/ DMSO [1029], Sinapinic acid [1030] Selective Histone deacetylases (HDAC) antagonists
Aspirin [1031], SRT2104 [1032], Corylin [1033] Sirtuin 1 (SIRT1) agonists
Liraglutide [1034], C12 [1035], NR [1036] Sirtuin 3 (SIRT3) agonists
Fingolimod [1037], Ozanimod [1038], Ginkgolic acid [1039] Sphingosine-1-phosphate (S1P) agonists
Drug [1040], MF-438 [1041], Sterculic oil [1042] stearoyl-CoA desaturase 1 (SCD1) antagonists
Drugs [1043], Compounds [1044], Flavonoids [1045] Suppressor of cytokine signaling 3 (SOCS-3) agonist
Phenformin [1046], Melanotan II [1047], Forskolin [1048] TBC1D1 agonists
Naloxone [1049], Resatorvid [1050], Yakuchinone [1051] A or B Toll-like receptor 4 (TLR4) antagonists
Saxagliptin [1052], SBI-477 [1053], Salidroside [1054] Thioredoxin-interacting protein (TXNIP) antagonists
Phencyclidine [1055]?, MG132, Cycloheximide [1056] Ubiquitin-conjugating enzyme E2O (UBE2O) antagonists
Parmodia [1057], CGP-12177 [1058], TetradecylThioacetic Acid [1059] Uncoupling protein-3 (UCP-3) agonists

Triacylglyceride biosynthesis
Roflumilast [1060], RS-2982 [1061], ACE [1062] 1-acylglycerol-3-phosphate acyltransferase (AGPAT) antagonists
Pradigastat [1063], AZD7687 [1064], Amidepsines [1065] Diacylglycerol O-acyltransferase 1 (DGAT1) antagonists
Canagliflozin [1066], H2-003&-005 [1067], QF [1068] Diacylglycerol O-acyltransferase 2 (DGAT2) antagonists
Naloxone [1069], iGP-5 [1070], Blumea balsamifera extract [1071] glycerol-3-phosphate dehydrogenase (GPDH) antagonists
Hydroxychloroquine [1072], MGAT4D-L [1073], 5‐CQA [1074] Monoacylglycerol acyltransferase (MGAT1) antagonists
Mipomersen [1075], JTP-103237 [1076], Rapamycin [1077] Monoacylglycerol acyltransferase (MGAT2) antagonists

Visceral Fat
Isofraxidin [1078], T-5224 [1079], Myricitrin [1080] ADAMTS5 antagonists
Drugs, Compounds [1081], Isovanillin [1082] Aldehyde oxidase (AO) antagonists
Olmesartan [1083], TRV055 [1084], Nitro-oleic acid [1085] Angiotensin II type 1 receptor (AT1R) antagonists
Bexarotene [1086], LGD1069 [1087], Picrasidine N [1088] Angiopoietin-like 4 (ANGPTL4) agonists
Mipomersen [1089], pB1 [1090], Glucosamine [1091] Apolipoprotein B-100 (apoB100) reducers
Bempedoic acid [1092], BMS-303141 [1093], Hydroxycitric acid [1094] ATP-citrate lyase (ACL) antagonists
Dasatinib [1095]?, QRFP-43 [1096], Green tea [1097] Caveolin-1 (CAV-1) antagonists
Adefovir Dipivoxil [1098], PGF2α [1099], rice hull smoke extract [1100] CCAAT-enhancer binding protein (C/EBPα/β) antagonists
Drug [1101], K579 [1102], Berberine [1103] Dipeptidyl peptidase-4 (DPP4) antagonists
Erlotinib [1104], 5-dAzaC [1105], Daidzein [1106] Glucocorticoid receptor β (GRβ) antagonists
Drug [1107], compounds [1108], mango ginger extract [1109] Glycosidase antagonists
Tirzepatide [1110], Onapristone [1111], PM extract [1112] IGF-binding protein 2 (IGFBP-2) agonists?
Alloxan [1113], Goblin1 [1114], Chromium [1115] O-GlcNAc transferase antagonists
Tesamorelin [1116], PAI-039 [1117], Loureirin B [1118] Plasminogen activator inhibitor-1 (PAI-1) antagonists
Menthol [1119], Drofenine [1120], Herbs [1121] Transient receptor potential cation channel, subfamily V, member 3 (TRPV3) agonists (might increase hunger)

White preadipocyte differentiation prevention
Flufenamic acid, 7alpha-diol [1122], Carnosic acid [1123] Aldo-keto reductase 1C2 (AKR1C2) antagonists
Osimertinib [1124], PD173952 [1125], Curcumin [1126] Amphiregulin (AREG) antagonists
Dihydrotachysterol (DHT), R1881 [1127], E. ulmoides extract [1128] Androgen receptor (AR) agonists
Teriparatide [1129]?, SNI-1 [1130], C.carthagenensi leafs [1131] Cell Cycle and Apoptosis Regulatory Protein (CARP-1/CCAR1) antagonists
Talazoparib [1132], PRMT5 [1133], Olive Leaf Extract [1134] (E2F1) antagonists
Lapatinib [1135], SLU-PP-1072 [1136], Eugenol [1137] Estrogen-related receptor α (ERRα) antagonists
Oxycodone [1138]?, Prokineticin 2, Cotinine [1139] G Protein-Coupled Receptor 73 (Prokr1/PKR1/Gpr73) agonists
Ipragliflozin [1140], Compounds [1141], Thapsigargin [1142] G-protein coupled receptor 78 (GPR78) antagonists
Gemfibrozil [1143], Compound A [1144], Vitamin A [1145] GATA binding protein 3 (GATA-3) agonists
Rosuvastatin [1146], Compounds [1147], MCP [1148] Galectin-3 (Gal-3) antagonists
Dexamethasone [1149], 17-beclomethasone monopropionate [1150], Baicalein [1151] GILZ agonists
Atropine [1152], AMP [1153], Denatonium benzoate [1154] Gustducin antagonists
TCM compounds [1155], GSA-10 [1156], Cyclopamine [1157] Hedgehog (HH) agonists
Hemin [1158], EET-A [1159], Cobalt protoporphyrin [1160] Heme oxygenase-1 (HO-1) agonists
Vorinostat [1161], Eticlopride [1162], Retinoic Acid [1163] Krüppel-like Factor 2 (KLF2) agonists
Metformin [1164], LYRM1 antibodies, α-Lipoic acid [1165] LYR motif containing 1 (LYRM1) antagonists
Lapatinib and OSU-03012 [1166], Aristolochic acid [1167] Nck1 antagonists
Crizotinib [1168], U0126 [1169], AKBA (indirectly) [1170]? Methionine adenosyltransferase 2B (MAT2B) antagonists
NSAIDs [1171], Compounds, Supplement [1172] Motilin antagonists
Paroxetine [1173], SR11237 [1174], Dong-Gui [1175] SRY-box transcription factor 9 (Sox9) agonists
Nafamostat [1176], NMM [1177], Carvacrol [1178] Transient receptor potential cation channel, subfamily M, member 7 (TRPM7) antagonist?
Clenbuterol [1179], AD198 [1180], KLA+PG [1181] Tubby-like protein superfamily member PLSCR3 agonists
Liraglutide [1182], Foxy5 [1183], Harmine [1184]? Wingless-related integration site 5A (WNT5a) agonists?

Treatments
EmsculptCoolsculptsculpsure, Exilis, Cavitation/Russian simulation device Fat loss devices
Gastric Bypass, LAP-BAND , The Obalon Balloon System Stomach reduction treatments
Liposuction, Laser lipolysis, abdominoplasty surgery Tummy shrinkers
Sodium deoxycholate w/ PPC (from aqualyx or lipo lab), Carboxytherapy, Lipotropic b12 injection treatments
Multiple acyl-CoA dehydrogenase deficiency (MADD) can develop users take multiple antiobesity drugs, so it's recommenced that researchers, doctors, and patients to use caution when dealing with these listed substances for weight loss or conditions.
If you do develop MADD, consider these pathways to combat the condition:
Triheptanoin [1185], CP775146 [1186], ALS-L1023 [1187] Very long‐chain acyl‐CoA dehydrogenase (VLCAD)
Bezafibrate [1188], CPU025 [1189], Tectorigenin [1190] Long-chain acyl-CoA dehydrogenase (LCAD) agonists
Increlex +WY-14643 [1191], GQD [1192] Medium chain acyl-CoA dehydrogenase (MCAD) agonists
Levocarnitine [1193], siRNA-1186 [1194], Vitamin b2 [1195] Short chain acyl-CoA dehydrogenase (SCAD) agonists
_____________________________________________________________________________________________________
14-3-3ζ is required for phagocytosis and invasive microbial resistance in vertebrates.
ACOT1 knockdown enhanced hepatic oxidative stress and inflammation.
ACSL1 deficiency improves insulin resistance, glucose homeostasis, and fat oxidation in adipose tissue, however, it increases protein catabolism, which causes muscle weakness, myocyte apoptosis, etc.
Adipotide can lead to kidney damage, likely by weakening patients' adipose renal capsules. Also if Adipotide's MOA ablates VEGF-A expression, it may cause whitening in BAT which might reduce thermogenesis.
AHR agonists prevents preadipocyte differentiation, but it also increases lipid accumulation.
ASCL1 plays a roll in fatty acid uptake, inhibiting his transcription factor will prevent hippocampal differentiation.
ATG7 studies show when the gene expression is KO'ed, the subjects displayed cases of extreme insulin sensitivity, but additionally, they displayed cases of hyperglycemia, mitochondrial dysfunction, and death of liver cells.
Baf60a increases the production of bile which can increase the absorption of the fats we eat, so in theory inhibiting would be beneficial for our purposes, however, inhibiting Baf60a reduces thermogenesis & normal body temperature.
BSCL2 increases browning but also increases food intake.
BMP4 agonists create WAT from preadipocytes while antagonists prevent adipocytic browning.
BMAL1 agonists can help with insulin sensitivity, however, they shorten the timing of eating periods, which can causes users to have shorter spans of satiety and increases their desire for more food.
C5L2 (A.K.A. C5aR2) agonists increase fat storage and triglyceride synthesis, but antagonists cause insulin resistance by up-regulating inflammatory cytokines.
C/EBPδ has a role in the forebrain, a part of the brain showing high levels of fibrillar Aβ deposits in Alzheimer's patients when the transcription factor is downregulated. In light of this, do not inhibit C/EBPδ unless it's absolutely necessary.
CaSR agonists improve insulin resistance and increases GLP-1 serum concentration, all the while, it causes preadipocyte to change into visceral adipocytes.
CALCR agonists?
CerS1/5 inhibitors might help with insulin resistance in the short term, but they also might cause muscle atrophy in the long term.
CGI-58 (AKA α/β hydrolase domain-containing protein 5) inhibition actives PPARγ which prevents obesity, but it causes hepatomegaly, NAFLD, inflammation, and insulin resistance.
CISD1/mitoNEET helps with insulin sensitivity, maintains mitochondrial function, and stops preadipocytes from maturing, but it also allows lipids to enter to fat cells and increases fat storage.
CNP inhibition/activation can lead to heart implications.
Cortisol induces lipolysis through GRα, however, when insulin is circulating in the body while GRβ's activated with cortisol, they increase visceral fat accumulation.
diacylglycerol kinases may induce preadipocytes into adipogenesis but it also has a part in CNS function.
DNP causes extreme hyperthermia and tachycardia, which lead to the deaths of many victims.
DGKδ causes preadipocyte to mature into adipocytes and increases triglyceride synthesis, in addition it regulates with skeletal muscle insulin sensitivity and neurological processes.
Dickkopf-3 expression helps with hepatic steatosis, alzheimer's disease, and insulin resistance, despite this, it also has been demonstrated to induce adipogenesis from preadipocytes.
E2F4?
ErbB4 impaired and improved the contextual-dependent fear expression
Gastric antagonistsy polypeptide (GIP) antagonists can increase one changes of pancreatic cancer, one of the most fatal types of cancer. Same can be said about LRH1 upregulation.
GLUT5 antagonists might induce irritable bowel syndrome. GLUT5 inhibitors maybe explain the negative side-effects of SGLT1 inhibitors
GPR30 increases adipocyte differentiation, also it regulates bone health and prevents myocardial fibrosis. Perhaps this is the receptor responsible for breast development and shortening of longitudinal bone growth.
HSP90 antagonists has some therapeutic promise with fat loss, most of these substances appear toxic.
ILK contributes to skeletal muscle insulin resistance, but when knockeddown the enzyme upregulated slow muscle proteins while it downregulated fast muscles which may not be that great for overall weight loss.
KLF5 initiates vascular smooth muscle cell proliferation and assists with vascular remodeling.
KLF15 overexpression induces cardiac hypertrophy, while deficiency might induce cardiac failure.
IGF2R inhibitors while they may reduce white adipocyte count, they're like likely to decrease one's IQ points by reducing neurological stem cell count.
LCHAD deficiency leads to lipolysis, not just in subcutaneous and visceral fat, but also in the brain and the kidneys, causing brain damage. In light of this, it's not suggested to use LCHAD inhibition as a viable method for fat loss.
LAMP2 deficiency showed resistance against hyperinsulinemic hyperglycemia and tissues lipid accumulation, however, it's also associated with cardiomyopathy and skeletal muscle weakness.
MEF2 agonism might induce cardiac hypertrophy.
MEG3 enhances hepatic insulin resistance and upregulates triglyceride content, but it also plays in muscle development and brain health.
obesogens [1196]
P2Y14 antagonists may reduce stem cells mobilization and negatively effect the immune system.
PKNOX1 inhibitors?
PPARβ & δ agonists, like GW501516, can enlarge the heart.
Prokineticin receptor-1&2 (PKR1&2) agonists have a major role in triggering and maintaining neuropathic pain.
PTH1R agonists.
RBP4 induces insulin resistance, especially in both skeletal and cardiac muscle, however, it prevents preadipocyte into adipocytes. This cytokine may also might cause browning.
ROR1 has a role in muscle regeneration and other protective effects, however, it may also promotes the proliferation of existing cancers and induce adipogenesis.
Sirtuin 7 (SIRT7) antagonists, like Fluorouracil [1197], can cause cardiomyocytic apoptosis.
Shh has plethora of regulatory functions throughout the body, including a role in insulin resistance, so inhibiting this protein would poses many (unnecessary) health risks to patients.
TRPC6 (along with TRPC3) even though it help to regulate glucose, it can amplify hypertrophic signaling in cardiomyocytes.
TRPML1/MCOLN1 inhibition could potentially reduce preadipocyte, and cancer, count, doing so could also induce adipogenesis, the development neurodegenerative & lysosome storage diseases, and shorter lifespan.
TWEAK/Fn14 agonists while might adipose tissue wasting, causes muscle atrophy.
ZAG plays a role in adipocyte browing, but it's also associated with insulin resistance in humans and is regulated by hyperglycemia, and hyperinsulinemia.
ZEB1 is an important transcription factor muscle regeneration, microglial regulation, and adipogenesis.

OTF, IRX2, IRX3, IRX5 ARID5B, rs1421085 are the genes linked to obesity. Hypothetically one could use CRISPR edit these DNA expression in their favor.

Share